Biovail’s Ralivia receives approvable letter

Share this article:
An item appearing in the December issue of Medical Marketing and Media (Pipeline, page 10) incorrectly stated that Biovail's Ralivia ER (tramadol hydrochloride) had received FDA approval.
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.